2015梅斯医学移动医疗创新大赛

2015-06-02 MedSci MedSci原创

移动医疗充满机会,但也亟待资源整合,寻找改善患者就医体验的移动医疗方案,挖掘互联网时代给移动医疗带来的创新策略,助力医疗及临床医学研究,提高临床诊疗效率。由梅斯医学举办的“2015梅斯医学移动医疗创新大赛”,本届大赛以“医路相伴,共赢未来”为主题,大赛将从所有参赛项目中筛选出10-15个项目参加决赛,优秀团队可获得20万、5万、1万资金奖励,当然,优胜团队也可获得“梅斯医学”后续开发者合作

移动医疗充满机会,但也亟待资源整合,寻找改善患者就医体验的移动医疗方案,挖掘互联网时代给移动医疗带来的创新策略,助力医疗及临床医学研究,提高临床诊疗效率。由梅斯医学举办的“2015梅斯医学移动医疗创新大赛”,本届大赛以“医路相伴,共赢未来”为主题,大赛将从所有参赛项目中筛选出10-15个项目参加决赛,优秀团队可获得20万、5万、1万资金奖励,当然,优胜团队也可获得“梅斯医学”后续开发者合作支持以及平台推广。

移动“医疗”发展方式遇到问题及瓶颈,医疗“移动”起来的时机到来,下一轮变革引擎的主体可以是医疗从业者,医疗借助移动技术做内部多层次的提升将进一步推动医疗发展。本次大赛目的只有一个:共同探索医疗服务的未来模式,助力医疗及临床医学研究,提高临床诊疗效率。只要你有想法,就带着你的创想来这里,实现你的移动医疗梦。

决赛将于2015628日在京举行,届时大赛将邀请移动医疗圈内权威人士,共同商讨移动医疗现状和发展方向。同时,对进入决赛的项目进行评分以及颁奖。优秀团队可获得资金奖励,一等奖(1名)奖励20万;二等奖(3名)奖金5万;三等奖(5名)奖金1万,当然,优胜团队也可获得“梅斯医学”后续开发者合作支持以及平台推广。

梅斯医学移动医疗创新大赛组委会诚邀以医生为项目的主导者,项目有临床专家作为核心团队支持,或在医院工作并对移动医疗感兴趣的个人或者团队来共享此大赛。项目提交截止日期2015619日,详情请点击大赛主页:http://medsci.cn/z/ydly0515/

【参赛要求】

以医生为项目的主导者,项目有临床专家作为核心团队支持,或在医院工作并对移动医疗感兴趣的个人或者团队都可参加

【项目要求】

1,参赛团队或个人提交助力医疗及临床医学研究,提高临床诊疗效率的解决方案,移动端的技术问题并不是关键内容。只要您有关于移动医疗创想,都可以参与。;

2,考虑整体的解决方案,而不仅限于技术平台的展示(暂无技术平台也可)

以上两点都不具备也没关系,只要你有想法,就带着你的创想来这里,实现你的移动医疗梦。

【参赛流程】

大赛报名:截止时间619

项目筛选:截止时间627

决赛及颁奖:2015628

【报名方式】

请点击大会官网:http://medsci.cn/z/ydly0515/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741141, encodeId=de7a1e411413a, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Fri Dec 04 04:42:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276768, encodeId=c23d12e6768c1, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285208, encodeId=c25d128520812, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530427, encodeId=0e94153042efd, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25828, encodeId=ed8925828a9, content=发挥智慧吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Wed Jun 03 09:08:00 CST 2015, time=2015-06-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741141, encodeId=de7a1e411413a, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Fri Dec 04 04:42:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276768, encodeId=c23d12e6768c1, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285208, encodeId=c25d128520812, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530427, encodeId=0e94153042efd, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25828, encodeId=ed8925828a9, content=发挥智慧吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Wed Jun 03 09:08:00 CST 2015, time=2015-06-03, status=1, ipAttribution=)]
    2015-06-04 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1741141, encodeId=de7a1e411413a, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Fri Dec 04 04:42:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276768, encodeId=c23d12e6768c1, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285208, encodeId=c25d128520812, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530427, encodeId=0e94153042efd, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25828, encodeId=ed8925828a9, content=发挥智慧吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Wed Jun 03 09:08:00 CST 2015, time=2015-06-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741141, encodeId=de7a1e411413a, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Fri Dec 04 04:42:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276768, encodeId=c23d12e6768c1, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285208, encodeId=c25d128520812, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530427, encodeId=0e94153042efd, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25828, encodeId=ed8925828a9, content=发挥智慧吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Wed Jun 03 09:08:00 CST 2015, time=2015-06-03, status=1, ipAttribution=)]
    2015-06-04 yahu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1741141, encodeId=de7a1e411413a, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Fri Dec 04 04:42:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276768, encodeId=c23d12e6768c1, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285208, encodeId=c25d128520812, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530427, encodeId=0e94153042efd, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Thu Jun 04 05:42:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25828, encodeId=ed8925828a9, content=发挥智慧吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Wed Jun 03 09:08:00 CST 2015, time=2015-06-03, status=1, ipAttribution=)]
    2015-06-03 Dr.LV

    发挥智慧吧

    0

相关资讯

移动医疗不会替代医生

英国《金融时报》中文网专访复星昆仲资本管理合伙人鲍周佳(FT中文网:FTC, 鲍周佳:Bao)FTC: 移动医疗在中国已经是一个很热门的话题,但对硬件厂商而言,找到一条清晰的商业模式依旧很困难。除了售卖设备,这个领域还有哪些价值可以挖掘?Bao:目前国内的移动医疗投资方兴未艾,很多创业公司和投资人会从各个角度布局市场,包括硬件、问诊平台、医患交流、在线药店等。其中一个最大的机会点,就是医疗级别的大

移动医疗, 医生或是下一轮变革引擎的主体?

“移动医疗”热潮一波一波来袭,从问诊平台,面向医生服务平台到BAT大佬,制药企业涌入。医生作为医疗体系中核心的主体,对改善医疗环境及提升医疗质量有着重要影响,医生可以是下一轮变革引擎的主体。 当移动遇到医疗,政策未放松 移动互联网快速改变了“通信、商品消费、金融等”,当它遇到医疗,更多却是围绕在体系外围打转,在面对移动互联网热潮,医疗体系显得格外的慎重,甚至于保守。2014年8月29日

飞涨的数据显示:可穿戴设备不是过眼烟云 市场正在成熟

可穿戴计算市场最热门的产品之一就是Fitbit、Misfit、Jawbone和in等厂商提供的健身和健康追踪设备,2014年这些设备的销量约为9000万部。消费者仍对使用这些产品来跟踪自身健康状况乐此不疲。 调研机构eMedCert研究人员近日收集了可穿戴市场一些有趣的数据,反映了用户对健康类可穿戴设备的兴趣和需求:  1. 2020年智能可穿戴健

中美移动医疗比较

 互联网领域,中美两国可谓齐头并进。全球市值最高的10家互联网公司,中国占据4席,美国占据6席。而在移动医疗/数字医疗领域,中美差距却比较大。比如,在美国,该领域的上市公司不下十家(比如Athena Health,Epocrates,Castlight),中国尚无一家。我们今天就来看看,在这个领域,中美两国有哪些重要的不同呢?用户方面 中:患者为主VS美:患、医、医院三分天下在用户方面,

俞熔:我眼中的移动医疗和健康大数据

移动医疗的四大竞争态势目前大家关注的移动医疗领域,其竞争态势可以分为以下四个方面:抢医生、争入口、拼线下、贴身体。目前医生的抢夺很严重,线上线下创新模式都围绕不可替代且稀缺的医生资源、稀缺资质的争抢。争抢医生存在这样一个显而易见的逻辑:有医生就不愁患者,有患者就有人买单。目前的争抢路径主要是:地推、用学术声望和利益捆绑医生。但学术、利益和情怀都是需要考虑的因素,谁能把这三个因素做到极致,谁将会在这

来瞧瞧,移动医疗如何影响医生对患者的健康管理?

移动技术升级将继续影响患者的健康管理今天,HIMSS15全球年会在美国芝加哥隆重召开。HIMSS发布了2015年移动医疗调查的结果。今天调查了超过200名医疗健康提供者员工,发现90%以上的调查对象对其病患进行健康管理时应用移动设备。同时,这份报告还显示了,调查对象相信移动医疗可促使健康管理成本的节约,同时提高健康管理的质量。90%的美国成人拥有移动设备,这使得移动医疗的应用在最近几年得到快速的发